About
The Alarming Rise in Road Fatalities: Why The Current Approach to Road Safety Isn’t Working

Road fatalities and injuries are a growing crisis. After decades of decline, the number of deaths on our roads has plateaued and, alarmingly, started to rise again. This concerning trend is particularly pronounced among vulnerable road users like pedestrians and cyclists, even as we invest more effort and money into road safety initiatives*. It begs the question: if we’re spending more, why aren’t we seeing better results?

The unfortunate truth is that current methods are often reactive, lack the crucial, real-time insights needed to truly impact safety. This is where a new era of technology emerges. Miovision Continuous Safety is designed to bridge this gap, transforming raw traffic data into actionable, life-saving decisions that directly support ambitious Vision Zero goals.

Learn How Miovision Continuous Safety Monitoring Can Help You:

✓ Pinpoint high-risk locations by identifying where and when near-miss events occur
✓ Conduct root cause analysis by analyzing video clips of conflict events.
✓ Accelerate safety improvements by iterative countermeasure evaluation
✓ Protect pedestrians and cyclists by identifying and prioritizing vulnerable road user safety.

Why Miovision?
As a global leader, Miovision serves over 70,000 intersections across North America and operates in 64 countries. Miovision is a trusted leader in solving today’s and tomorrow’s traffic challenges—including road safety—helping cities shift from reactive to proactive road safety management and ensuring safer streets for all road users. We have a proven track record of supporting local governments with the tools, expertise, and strategic guidance needed to realize impactful transportation projects. We’re here to be your partner in working towards Vision Zero.
When
Wednesday, October 1, 2025 · 3:00 p.m. London (GMT +1:00)
Presenters
1755763718-3d86e661b8f93387
Craig Milligan, Ph.D., P.Eng., RSP2I
Senior Road Safety Engineer
As an international expert in road safety engineering, Dr. Craig Milligan has completed more than 600 intersection safety studies, road safety audits for more than $8B of capital works, road safety network prioritization tools for four road agencies, 10 road safety technical guidelines, and 30 research papers in road safety. Craig is a past chair of the Transportation Association of Canada Road Safety Standing Committee, and a current board member and road safety audit instructor with the International Road Federation. Craig earned his Ph.D. in civil engineering at the University of Manitoba with a focus on road safety performance forecasting. Craig has been retained by more than 120 road authorities on four continents for expert support in road safety.
1755763746-bf7cc5c4bb4c9a5b
Tom Stone
Editor
Tom has edited Traffic Technology International (TTi) magazine and its Traffic Technology Today website since May 2014. During his time at the title, he has interviewed some of the top transportation chiefs at public agencies around the world as well as CEOs of leading multinationals and ground-breaking start-ups. Tom's earlier career saw him working on some the UK's leading consumer magazine titles. He has a law degree from the London School of Economics (LSE).
Reserve Your Spot
Full name*
Email Address*
Country*
County / State*
Company*
Job Title*
Telephone*
Privacy Policy and Contact Preferences
Please read our Privacy Policy below. This will explain how we process, use and safeguard your data. In addition to this service, this magazine, other parts of the Mark Allen Group and partner organisations would like to contact you about events, products & services that we think will be of interest to you. If you would like to update your marketing preferences, please go here: https://contactpreferences.markallengroup.com.
I understand*
We use BigMarker as our webinar platform. By clicking Register, you acknowledge that the information you provide will be transferred to BigMarker processing in accordance with their Terms of Service and Privacy Policy.